文献速递湿疹皮炎与荨麻疹

Delgocitinib乳膏治疗成人慢性手部湿疹长达52周的安全性和有效性:DELTA 3开放标签扩展试验

Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials.
PubMed 文献 · J Am Acad Dermatol · 2025-03-11

DELTA 3是一项3期开放标签扩展试验,纳入完成DELTA 1和2试验16周治疗期的801例慢性手部湿疹患者,按需使用Delgocitinib乳膏20 mg/g每日两次治疗36周。结果显示Delgocitinib耐受性良好,最常见不良事件为COVID-19和鼻咽炎,且能维持疾病控制长达52周。

要点

  • Delgocitinib乳膏20 mg/g按需每日两次治疗36周耐受性良好。
  • 在母试验中接受Delgocitinib治疗的患者,IGA-CHE 0/1和HECSI-75/90应答维持至第36周。
  • 既往使用赋形剂乳膏的患者,相应应答率从DELTA 3基线改善至第36周。

核心结论

  • Delgocitinib乳膏治疗慢性手部湿疹耐受性良好,并能维持疾病控制长达52周。

研究设计与样本

  • 3期开放标签扩展试验DELTA 3(NCT04949841),纳入完成DELTA 1和2试验16周治疗期的成人慢性手部湿疹患者801例,按需使用Delgocitinib乳膏20 mg/g每日两次治疗36周。

主要发现

  • Delgocitinib耐受性良好(n=801;R=231.1;患者观察年数=535.7),最常见不良事件为COVID-19和鼻咽炎。
  • 在母试验中接受Delgocitinib治疗的患者,DELTA 3基线IGA-CHE 0/1为24.6%,HECSI-75/HECSI-90为51.8%/31.8%,维持至第36周分别为30.0%和58.6%/36.6%。
  • 既往使用赋形剂乳膏的患者,相应应答率从DELTA 3基线(9.1%和23.7%/12.0%)改善至第36周(29.5%和51.5%/35.7%)。

关键数值与推荐

  • 主要终点为治疗中出现的不良事件数量。
  • 关键次要终点为IGA-CHE 0/1和HECSI-75/90应答率。
  • IGA-CHE≥2的患者接受治疗直至达到IGA-CHE≤1。

临床怎么用

  • Delgocitinib乳膏20 mg/g可按需每日两次用于成人慢性手部湿疹的长期维持治疗。

局限性

  • 开放标签试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Delgocitinib cream is the only topical treatment that has been specifically developed and approved for moderate to severe Chronic Hand Eczema (CHE). OBJECTIVE: The objective of this trial was to evaluate the long-term safety and efficacy of delgocitinib cream 20 mg/g as needed for 36 weeks in adults with CHE. METHODS: In phase 3 open-label DELTA 3 (NCT04949841), patients who completed the 16-week treatment period in the DELTA 1 and 2 trials were treated on an as-needed basis with twice-daily delgocitinib cream for 36 weeks (n= 801). Patients with Investigator's Global Assessment for CHE (IGA-CHE) ≥2 received treatment until IGA-CHE ≤1 was achieved. The primary endpoint was the number of treatment-emergent adverse events. Key secondary endpoints were IGA-CHE 0/1 and ≥75%/≥90% improvement in Hand Eczema Severity Index (HECSI-75/90) scores. RESULTS: Delgocitinib was well-tolerated (n= 801; R = 231.1; patient years of observation = 535.7), with most frequent adverse events being COVID-19 and nasopharyngitis. DELTA 3 baseline IGA-CHE 0/1 (24.6%) and HECSI-75/HECSI-90 (51.8%/31.8%) were maintained to week 36 (30.0% and 58.6%/36.6%, respectively) among delgocitinib-treated patients in the parent trials. Among those previously treated with cream vehicle, corresponding response rates improved from DELTA 3 baseline (9.1% and 23.7%/12.0%, respectively) to week 36 (29.5% and 51.5%/35.7%). LIMITATIONS: Open-label trial. CONCLUSION: Delgocitinib cream treatment was well-tolerated and efficacious in maintaining disease control in patients with CHE for up to 52 weeks.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Gooderham M, Molin S, Bissonnette R, et al. Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials. J Am Acad Dermatol. 2025. PMID: 40081663. doi:10.1016/j.jaad.2025.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。